Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Molecular Mechanisms of Cutaneous Immune-Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitors
Yi-Shan Teng, Sebastian Yu
Current Oncology (2023) Vol. 30, Iss. 7, pp. 6805-6819
Open Access | Times Cited: 22

Showing 22 citing articles:

Emerging Insights into Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Induced by Immune Checkpoint Inhibitor and Tumor-Targeted Therapy
Min Lin, Ting Gong, Shi‐Fan Ruan, et al.
Journal of Inflammation Research (2024) Vol. Volume 17, pp. 2337-2351
Open Access | Times Cited: 6
Opportunities and challenges of immuno-oncology: A bibliometric analysis from 2014 to 2023
Siqi Zhang, Lina Miao, Xiaoxia Tian, et al.
Human Vaccines & Immunotherapeutics (2025) Vol. 21, Iss. 1
Open Access
Case Report: The immune architecture of immunotherapy-induced cutaneous sarcoidosis resembles peritumoral inflammation
Catherine J. Wang, Jennifer Strong, Margaret E. Gatti‐Mays, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Case Report: Multiple cutaneous keratoacanthoma-like lesions in a colorectal cancer patient treated with sintilimab
Shiyi Li, Xianhui Ye, Xiaofen Li, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Research Progress on Adverse Events of Immune Checkpoint Inhibitors
洪益 肖
Advances in Clinical Medicine (2025) Vol. 15, Iss. 03, pp. 1493-1500
Closed Access
Dermatologic toxicities related to cancer immunotherapy
Yosra Vaez-Gharamaleki, Mohammad Amin Akbarzadeh, Farhad Jadidi‐Niaragh, et al.
Toxicology Reports (2025), pp. 102021-102021
Open Access
From clinical observations to molecular insights: Decoding immune checkpoint inhibitors‐induced prostatitis
Peng Luo, Ying Liu, Lan Xu, et al.
View (2025)
Open Access
Symptom clusters and their impacts on the quality of life of patients with lung cancer receiving immunotherapy: A cross‐sectional study
Xuying Yang, Jingcui Bai, Jinhuang Zhang, et al.
Journal of Clinical Nursing (2024)
Closed Access | Times Cited: 4
Case report: Envafolimab causes local skin necrosis
Jing Jing Liu, Xiao Ya Xu, Huan Han, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
Immunological landscape of solid cancer: Interplay between tumor and autoimmunity
Ajay Singh, Phaneendra K. Duddempudi, Divya Kenchappa, et al.
International review of cell and molecular biology (2024), pp. 163-235
Closed Access | Times Cited: 1
Immune checkpoint inhibitors and renal toxicity
Federica Bocchi, Simon Häfliger, Simone Schmid, et al.
Heliyon (2024) Vol. 10, Iss. 11, pp. e31911-e31911
Open Access | Times Cited: 1
Superficial mucoceles as a sequel to Stevens‑Johnson syndrome during treatment of cutaneous squamous cell carcinoma with cemiplimab: A case report and review of literature
Vasiliki Chwiałkowska, Monika Słowińska, Anna Płatkowska, et al.
Experimental and Therapeutic Medicine (2024) Vol. 29, Iss. 1
Open Access | Times Cited: 1
Symptom Clusters and Symptom Network Analysis During Immunotherapy in Lung Cancer Patients
Xuying Yang, Jincui Bai, R. Liu, et al.
Research Square (Research Square) (2024)
Open Access
Glucocorticoids in lung cancer: Navigating the balance between immunosuppression and therapeutic efficacy
Wenhui Xu, Jinghong Ye, Zhen‐Dong Cao, et al.
Heliyon (2024) Vol. 10, Iss. 12, pp. e32357-e32357
Open Access
Tislelizumab-Induced Toxic Epidermal Necrolysis-Like Cutaneous Adverse Reaction: Rare Complication of Immune Checkpoint Inhibitor Therapy
Yang Xiaoqin, XU Shun-ming
American Journal of Therapeutics (2024) Vol. 31, Iss. 4, pp. e470-e474
Closed Access
Immune Checkpoint Inhibitors for Pediatric Cancers: Is It Still a Stalemate?
Tang‐Her Jaing, Yi-Lun Wang, Chia-Chi Chiu
Pharmaceuticals (2024) Vol. 17, Iss. 8, pp. 991-991
Open Access
Erythema multiforme associated with the immune checkpoint inhibitors: A disproportionality analysis using the FDA Adverse Event Reporting System
Hannah Godfrey, Zachary Leibovit‐Reiben, Patrick Jedlowski, et al.
Journal of the American Academy of Dermatology (2024) Vol. 91, Iss. 6, pp. 1233-1234
Closed Access
Symptom clusters and symptom network analysis during immunotherapy in lung cancer patients
Xuying Yang, Jingcui Bai, Ruili Liu, et al.
Supportive Care in Cancer (2024) Vol. 32, Iss. 11
Closed Access
Adverse skin reactions secondary to sintilimab for advanced gastric adenocarcinoma: A case report and literature review
Yuru Bai, Hong Chen, Youyou Duanmu, et al.
Molecular and Clinical Oncology (2024) Vol. 22, Iss. 1
Open Access
Challenges and advances of immune checkpoint therapy
Lingyu Li, Yingli Sun
Clinical and Translational Discovery (2024) Vol. 4, Iss. 6
Open Access
Ocular Immune-Related Adverse Events Associated with PD-1 Inhibitors: From Molecular Mechanisms to Clinical Management
Yuqi Gong, Yushuai Liu, Fagang Jiang, et al.
Seminars in Ophthalmology (2024), pp. 1-18
Closed Access
Physiological markers for immunotherapeutics: a review
Durlav Chowdhury, Ashmita Das, Mrityunjay Mishra, et al.
Journal of Chemotherapy (2024), pp. 1-24
Closed Access
Immune Checkpoint Inhibitor-Associated Cutaneous Adverse Events: Mechanisms of Occurrence
Abdulaziz M. Eshaq, Thomas W. Flanagan, Anass Abbad, et al.
International Journal of Molecular Sciences (2024) Vol. 26, Iss. 1, pp. 88-88
Open Access
Symptom Clusters and Quality of Life in Patients With Lung Cancer Receiving Immunotherapy in China
Xuying Yang, Xuehua Zhu, Jingcui Bai, et al.
Research Square (Research Square) (2023)
Open Access
Page 1

Scroll to top